An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome

類似資料

• An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
  著者:: Talreja, Vikas T., 等
  出版事項: (2019)
• Synchronous primary of periampullary and lung cancer: A case report and review of literature
  著者:: Vikas Talreja, 等
  出版事項: (2018-01-01)
• Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
  著者:: Talreja, Vikas T., 等
  出版事項: (2020)
• Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
  著者:: Talreja, Vikas T., 等
  出版事項: (2019)
• Metastatic Renal Cell Cancer—Systemic Therapy
  著者:: Joshi, Amit, 等
  出版事項: (2018)